

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) APR 19 2004			Docket Number (Optional) ISA-004.01		Application Number 10/618,567	
			Applicant Ng, Leong			
			Filing Date July 11, 2003		Group Art Unit 1651 1641	
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JLG	A1	5,290,678	03/01/94	Jackowski		
	A2	5,604,105	02/18/97	Jackowski		
	A3	5,710,008	01/20/98	Jackowski		
	A4	6,348,585	02/19/02	Culp et al.		
JLG	A5	6,534,322	03/18/03	Sabbadini		
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation YES NO
JLG	B1	WO 00/31265	06/02/00	PCT		Abstract only
JLG	B2	EP 1 241 479 A2	09/18/02	European Patent Application		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages Etc.)						
JLG	C1	Russell Hart and Laurence Taaffe, (1987) "The use of acridinium ester-labelled streptavidin in immunoassays," <i>Journal of Immunological Methods</i> , Vol. 101: pp. 91-96				
	C2	Brenner et al., (1990) "Diverse Biological Actions of Atrial Natriuretic Peptide," <i>Physiological Reviews</i> , Vol. 70, No. 3: pp. 665-699				
	C3	Koller et al., (1991) "Selective Activation of the B Natriuretic Peptide Receptor by C-Type Natriuretic Peptide (CNP)," <i>Science</i> , Vol. 252: pp.120-123				
	C4	Stingo et al., (1992) "Cardiovascular and renal actions of C-type natriuretic peptide," <i>The American Physiological Society</i> , H308-H312				
	C5	Stingo et al., (1992) "Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma" <i>The American Physiological Society</i> , H1318-H1321				
	C6	Suga et al., (1992) "Endothelial Production of C-Type Natriuretic Peptide and Its Marked Augmentation by Transforming Growth Factor- β ," <i>J. Clin. Invest.</i> , Vol. 90: pp. 1145-1149				
	C7	Sumar et al., (1993) "Lectins as indicators of disease-associated glycoforms," <i>In HJ Gavius, S Gavius, eds., Lectins and Glycobiology, Springer Laboratory</i> : pp 158-174				
JLG	C8	Johannes Mair, MD et al., (1995) "A Decision Tree for the Early Diagnosis of Acute Myocardial Infarction in Nontraumatic Chest Pain Patients at Hospital Admission," <i>Chest</i> , Vol. 106, No. 6: pp. 1502-1509				
EXAMINER	/James L. Grun/			DATE CONSIDERED 06/14/2006		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.						

Form PTO-1449		Docket Number (Optional) ISA-004.01		Application Number 10/618,567	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Ng, Leong		Group Art Unit 1641	
		Filing Date July 11, 2003			
JLG		Robert S. Ames et al., (1999) "Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14", <i>Nature</i> , Vol. 401: pp. 282-286			
JLG	C10	Hughes <i>et al.</i> , (1999) "An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction," <i>Clinical Science</i> ; Vol. 96: pp. 373-380			
	C11	J. Karl et al. (1999) "Development of a novel, N-Terminal-proBNP (NT-proBNP) assay with a low detection limit," <i>Scand. J. Clin. Lab Invest.</i> , Vol. 59, Suppl. 230: pp. 177-181			
	C12	Bottrill <i>et al.</i> , (2000) "Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries," <i>British Journal of Pharmacology</i> , Vol. 130, No. 8: pp.1865-1870			
	C13	Douglas <i>et al.</i> (2000) "Human Urotensin-II is a Potent Vasoactive Peptide: Pharmacological Characterization in the Rat, Mouse, Dog and Primate," <i>Journal of Cardiovascular Pharmacology</i> , Vol. 36, Suppl. 1: S163-S166			
	C14	Tzanidis <i>et al.</i> , (2000) "Urotensin-II stimulates collagen synthesis by cardiac fibroblasts in vitro: implications for myocardial remodelling," ABSTRACT			
	C15	Christian Hall (2001) "The value of natriuretic peptides for the management of heart failure: current state of play," <i>European Journal of Heart Failure</i> , Vol. 3: pp. 395-397			
	C16	C. Hillier <i>et al.</i> , (2001) "Effects of Urotensin II in Human Arteries and Veins of Varying Caliber," <i>Circulation</i> ; Vol. 103 : pp. 1378-1381			
	C17	Russell <i>et al.</i> (2001) "Cardiostimulant effects of urotensin-II in human heart <i>in vitro</i> ," <i>British Journal of Pharmacology</i> , Vol. 132: pp. 5-9			
	C18	Stirrat <i>et al.</i> (2001) "Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries," <i>Am. J. Heart Circ. Physiol.</i> , Vol. 280: pp. H925-H928			
	C19	Watanabe <i>et al.</i> , (2001) "Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation," <i>Journal of Hypertension</i> ; Vol. 19, No. 12: pp. 2191-2196			
	C20	Zou <i>et al.</i> , (2001) "Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats," <i>Federation of European Biochemical Societies Letters</i> , Vol. 508: pp. 57-60			
	C21	Douglas <i>et al.</i> , (2002) "Congestive heart failure and expression of myocardial urotensin II," <i>The Lancet</i> , Vol. 359: pp. 1990-1997			
	C22	Pearson et al., (1980) "Urotensin II: A somatostatin-like peptide in the caudal neurosecretory system of fishes," <i>PNAS</i> , Vol. 77, No. 8: pp. 5021-5024			
JLG	C23	Coulouarn et al., (1998) "Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord" <i>PNAS</i> , Vol. 95: pp. 15803-15808			
EXAMINER		/James L. Grun/		DATE CONSIDERED 06/14/2006	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.					

Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
(Use several sheets if necessary)

Docket Number (Optional)

ISA-004.01

Application Number

10/618,567

Applicant
Ng, LeongFiling Date
July 11, 2003

Group Art Unit 1641

~~1651~~**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
JLG	B3 WO 02/32932	04/25/02	PCT				

OTHER DOCUMENTS*(Including Author, Title, Date, Pertinent Pages Etc.)*

JLG	C24	Douglas et al., "Human Urotensin-II, the Most Potent Mammalian Vasoconstrictor Identified to Date, as a Therapeutic Target for the Management of Cardiovascular Disease, Trends in Cardiovascular Medicine, 10(6):229-237 (2000)					
JLG	C25	Ng et al., "Plasma Urotensin in Human Systolic Heart Failure," <i>Circulation</i> 2002, 106: 2877-2880.					
JLG	C26	Russell et al., "Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure," <i>Am. J. Physiol. Heart Circ. Physiol.</i> 285:H1576-H1581 (2003)					
JLG	C27	Tzanidis et al., "Direct Actions of Urotensin II on the Heart Implications for Cardiac Fibrosis and Hypertrophy," <i>Circulation Research</i> , 93(3):246-253 (2003)					
EXAMINER	/James L. Grun/			DATE CONSIDERED			
				06/14/2006			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.